Mineralys Therapeutics, Inc. (MLYS) FY2025 10-K Annual Report
Mineralys Therapeutics, Inc. (MLYS) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 12, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Mineralys Therapeutics, Inc. FY2025 10-K Analysis
Business Overview
- • Business section lacks substantive description of core operations or products
- • Reliance on 2026 Proxy Statement for key corporate governance and executive compensation details
- • No disclosure of new products, services, strategic shifts, or geographic expansions this year
- • References Ernst & Young LLP as principal independent auditor for 2026 financial statements
- • Unusual focus on compliance codes and proxy statement incorporation, minimal direct business narrative
Management Discussion & Analysis
- • No revenue; net loss $154.7M in 2025 vs $177.8M in 2024, improvement of $23.1M
- • R&D expenses $132.0M in 2025 vs $168.6M in 2024, a 21.7% decrease; G&A expenses $38.6M vs $23.8M, a 62.0% increase
- • No segments disclosed; entire focus on lorundrostat development and clinical trials
- • Cash, cash equivalents, and investments $656.6M at year-end 2025; raised $269.6M in Sept 2025, $188.7M in Mar 2025, and $139.6M via ATM offering through Mar 2026
- • Management expects cash to fund operations for at least 12 months; key risk is timing and success of regulatory approval and clinical trial outcomes
Risk Factors
- • Regulatory risk: FDA review pending for lorundrostat NDA submitted December 22, 2025, with no prior approvals or revenue
- • Macroeconomic risk: Global economic volatility and geopolitical conflicts (Ukraine, Israel, Venezuela) may restrict capital availability for operations
- • Supply chain risk: Dependency on third-party CMOs for cGMP-compliant manufacturing scale-up of lorundrostat, potential delays and cost increases
- • Competitive risk: Market acceptance risk due to potential competing products and alternative therapies affecting lorundrostat launch prospects
- • Financial risk: Accumulated deficit $457.2M with net losses $154.7M in 2025; need substantial capital raises risking dilution or restrictive debt covenants
Mineralys Therapeutics, Inc. FY2025 Key Financial MetricsXBRL
Net Income
-$155M
▲ +13.0% YoY
ROE
-23.9%
▲ +6906bp YoY
Total Assets
$662M
▲ +221.4% YoY
EPS (Diluted)
$-2.29
▲ +37.4% YoY
Operating Cash Flow
-$142M
▲ +14.4% YoY
Source: XBRL data from Mineralys Therapeutics, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Mineralys Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.